- Home
- » Tags
- » Sitagliptin
Top View
- File Download
- DPP-4 Inhibitors and Heart Failure
- Pre-Surgery Diabetes Medications
- Evaluation of Insulin Glargine in Combination with Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial
- Janumet, INN-Sitagliptin/Metformin
- Merck Provides Update on Filing Plans for Omarigliptin, an Investigational DPP-4 Inhibitor for Type 2 Diabetes
- SUPPLEMENTARY DATA Supplementary
- (EXE) Or Sitagliptin (SITA) to Combination Therapy with Insulin Glargine (GLAR) and Metformin (MET) – a Proof-Of-Concept Study
- Insulin Therapy Management
- Rifamycins and Anti-Diabetic Agents: Drug-Drug Interactions
- Comparison of the Efficacy of Sitagliptin with Pioglitazone on Blood Glucose Control in Type 2 Diabetic Patients
- Januvia (Sitagliptin) Basics Powered by Lowers Your Blood Sugar
- Long-Term Efficacy of Glibenclamide and Sitagliptin Therapy in Adult
- Insulin and Combination Agents TCO 08.2020
- Clinical Study Report
- Janumet XR (Sitagliptin/Metformin Extended-Release)
- IRB00082180 NCT02556918 Sitagliptin for the Prevention and Treatment of Hyperglycemia in Patients with Type 2 Diabetes Undergoin
- Diabetes Management Medications
- Dipeptidyl Peptidase-4 Inhibitors Clinical Data and Clinical Implications
- Januvia (Sitagliptin)
- Sitagliptin Monograph
- New Incretin Therapies Require Thoughtful Use
- Individualize the Dosage of JANUMET on the Basis of the Patient's O O The
- Insulin Degludec (Tresiba®, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
- JANUMET (Sitagliptin and Metformin Hcl) Tablets Metabolic Acidosis, Including Diabetic Ketoacidosis
- Repositioning of Omarigliptin As a Once-Weekly Intranasal Anti- Parkinsonian Agent Received: 14 February 2018 Bassam M
- Cost-Minimization Analysis of Linagliptin Compared to Sitagliptin
- Insulin Lispro with Continuous Subcutaneous Insulin Infusion Is Safe
- Product Information for Sitagliptin/Metformin
- Canagliflozin) Tablets, for Oral Use INVOKANA, Assess and Correct Volume Status in Patients with Renal Initial U.S
- Dipeptidyl Peptidase-4 Inhibition Stimulates Distal Tubular
- Insulin and Combination Agents TCO 02.2021
- Diabetes Medications Dosing Guide
- INVOKAMET+XR-Pi.Pdf
- The Future of Insulin Therapy for Patients with Type 2 Diabetes Mellitus Joseph M
- Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus
- Biasp 30) with Sitagliptin, And
- Canagliflozin for Type 2 Diabetes: an Up-To-Date Evidence Summary
- Sitagliptin | Memorial Sloan Kettering Cancer Center
- Clinical Review
- A Comprehensive Review and Perspective on Natural Sources As Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes
- Omarigliptin
- Canagliflozin Phase 3 Program Media Fact Sheet
- FDA Warns That DPP-4 Inhibitors for Type 2 Diabetes May Cause Severe Joint Pain
- Efficacy and Safety of Sitagliptin Added to Metformin and Insulin Compared
- Sitagliptin Januvia™ — Merck Frosst Canada Inc
- JANUMET Label
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin
- Synthesis of New DPP-4 Inhibitors Based on a Novel Tricyclic Scaffold
- Incretin Mimetics and Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes
- Triple Combination of Insulin Glargine, Sitagliptin and Metformin in Type 2 Diabetes: the EASIE Post-Hoc Analysis and Extension Trial
- Januvia, INN-Sitagliptin
- Antihyperglycemic Agents Comparison Chart
- Sitagliptin (JANUVIA®)
- Alogliptin (Vipidia™) Sitagliptin(Januvia™) and Linagliptin (Trajenta™) for Type 2 Diabetes
- Effect of Exenatide, Sitagliptin, Or Glimepiride on Β-Cell Secretory
- Medication Guide JANUVIA® (Jah-NEW-Vee-Ah) (Sitagliptin) Tablets, for Oral Use
- TRESIBA® (Insulin Degludec Injection) Label
- Canagliflozin Compared with Sitagliptin For
- SGLT2 INHIBITORS Invokana
- Evidencefinder Last Updated May 7, 2020
- Triple Combination of Insulin Glargine, Sitagliptin and Metformin in Type 2 Diabetes: the EASIE Post-Hoc Analysis and Extension Trial
- JANUVIA Safely and Effectively
- Sitagliptin Treatment at the Time of Hospitalization Was Associated
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- Sitagliptin, Linagliptin)
- JANUVIA, INN: Sitagliptin
- Canagliflozin in Combination Therapy for Treating Type 2 Diabetes
- Sitagliptin/Pioglitazone) and Related Names